Company intelligence / Profile preview

Apmonia Therapeutics

Strasbourg, Grand Est, Franceapmonia-therapeutics.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Apmonia Therapeutics has developed a first-in-class therapeutic peptide (TAX2) targeting TSP-1 in the tumor microenvironment. The company aims to combine this therapy with a companion diagnostic kit for patient stratification. Recent funding and collaborations are supporting advancement toward clinical trials, but no published late-stage clinical results yet.

Therapeutic areas: Oncology
Modalities: Peptides (notably therapeutic peptides)immunotherapy
Industry: Biotech

Drug pipeline

2 assets

TAX2

1 more asset in the full pipeline.

Request access →

Partnerships

SATT Nord (licensing and co-development agreement)Max Mousseron Institute of Biomolecules / IBMM (collaboration in molecular modeling)Bpifrance as public sector investor/funder

Beyond the preview

Go deeper on Apmonia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apmonia Therapeutics.

Explore the full profile